Search Clinical Trials
Sponsor Condition of Interest |
---|
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co. Ltd
Relapsed or Refractory T Cell Lymphoma
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary
efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma expand
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma Type: Interventional Start Date: Dec 2021 |
Cycled Phototherapy
NICHD Neonatal Research Network
Hyper Bilirubinemia
Premature Infant
Cycled phototherapy (PT) is likely to increase survival over that with continuous PT
among extremely premature infants (< 750 g BW or <27 weeks GA). expand
Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (< 750 g BW or <27 weeks GA). Type: Interventional Start Date: Jul 2020 |
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
ECOG-ACRIN Cancer Research Group
Breast Screening
This randomized phase III trial studies digital tomosynthesis mammography and digital
mammography in screening patients for breast cancer. Screening for breast cancer with
tomosynthesis mammography may be superior to digital mammography for breast cancer
screening and may help reduce the need for... expand
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment. Type: Interventional Start Date: Sep 2017 |
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
Hematologic Malignancies
Inherited Disorders of Metabolism
Inherited Abnormalities of Platelets
Histiocytic Disorders
Acute Myelogenous Leukemia (AML or ANLL)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications. expand
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Type: Observational Start Date: Oct 2011 |
Gut Oxalate Absorption in Calcium Oxalate Stone Disease
University of Alabama at Birmingham
Kidney Stone
Kidney Calculi
Urolithiasis
Urolithiasis, Calcium Oxalate
Nephrolithiasis
The goal of this clinical trial study is to test if patients with idiopathic calcium
oxalate kidney stones have an increased absorption of dietary oxalate, which would lead
to increased urinary excretion of oxalate.
The study will recruit adult patients with a history of calcium oxalate kidney stones... expand
The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate. The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones. Participants will - ingest fixed diets containing low and moderately high amounts of oxalate for 5 days at a time - ingest a soluble form of oxalate and sugar preparations to test gut permeability - collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test Type: Interventional Start Date: Apr 2024 |
O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease
University of Alabama at Birmingham
Kidney Stone
Kidney Calculi
Urolithiasis
Urolithiasis, Calcium Oxalate
Nephrolithiasis
The goal of this trial is to test if colonization with the gut bacteria Oxalobacter
formigenes leads to a reduction in urinary oxalate excretion in patients with calcium
oxalate kidney stone disease.
The study will recruit adult participants with a history of calcium oxalate kidney stones
who are... expand
The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease. The study will recruit adult participants with a history of calcium oxalate kidney stones who are not colonized with Oxalobacter formigenes. Participants will - ingest fixed diets containing low and moderately high amounts of oxalate for 4 days at a time - collect urine, blood and stool samples during the fixed diets - ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes Type: Interventional Start Date: Apr 2024 |
Long COVID Brain Fog: Cognitive Rehabilitation Trial
University of Alabama at Birmingham
Long COVID
Brain Fog
Cognitive Impairment
Cognitive Dysfunction
Post-Acute COVID-19 Syndrome
This study will compare two approaches to cognitive rehabilitation in adults with long
COVID with persistent, mild to moderate, cognitive impairment. One approach will feature
(A) web-based computer "games" that trains how quickly individuals process information
that they receive through their senses;... expand
This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer "games" that trains how quickly individuals process information that they receive through their senses; (B) in-lab training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation (VNS), i.e., trans-auricular VNS (taVNS). Component B will include work-related tasks. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will feature (A) web-based computer "games" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, healthy nutrition, and healthy sleep, (C) procedures designed to promote integration of these lifestyle changes into everyday life, and (D) taVNS. This approach is termed Brain Fitness Training (BFT). A subset of participants, who qualify for and and desire vocational rehabilitation (VR), will receive VR from the Alabama Department of Rehabilitation Services (ADRS) in addition to CICT or BFT. ADRS VR will include career counseling, prescription of on-the-job accommodations, and guidance on return-to-work. Those in the CICT + VR group will also receive on-the-job coaching from a peer mentor for a month after completing training. CICT, with or without VR, will involve 30 hours of training. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life and improving skills essential to work; the set of the latter procedures is termed the Transfer Package. ta-VNS will administered for 10 minutes before gaming and in-lab target behavior training. To accommodate the demands of participants' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life. BFT, with or without VR, will involve 30 hours of training following the same schedule as for CICT. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors (healthy sleep, nutrition and relaxation habits) and the procedures designed to promote transfer of behavior change to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life. Participants will be randomly assigned to the interventions. Randomization will be stratified by whether participants qualify for and desire VR from ADRS or not. If yes, participants will be randomized in equal numbers to CICT + VR or BFT + VR. If no, participants will be randomized in equal numbers to CICT or BFT. Testing will happen one month before treatment, one day before treatment, one day afterwards, and 6- and 12-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life. Another important outcome measure will be whether or not participants were able to return back to work or had significant improvements in their work activities. Type: Interventional Start Date: Apr 2024 |
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment...
National Cancer Institute (NCI)
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to
selumetinib alone in women with endometrial or ovarian (fallopian tube and primary
peritoneal) cancer that has come back (recurrent) or that remains despite treatment
(persistent) and harbors a mutation in the RAS pathway.... expand
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone. Type: Interventional Start Date: Apr 2023 |
Oxalate-Driven Host Responses in Kidney Stone Disease
University of Alabama at Birmingham
Kidney Stones
This study is looking to understand the role of oxalate on kidney stone development and
immunity. This study will enroll healthy participants and participants with calcium
oxalate kidney stones (CaOx KS). Participants will be in this study for about 3 weeks,
consume controlled diets, and provide blood... expand
This study is looking to understand the role of oxalate on kidney stone development and immunity. This study will enroll healthy participants and participants with calcium oxalate kidney stones (CaOx KS). Participants will be in this study for about 3 weeks, consume controlled diets, and provide blood and urine specimens. Type: Interventional Start Date: May 2023 |
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
Varian, a Siemens Healthineers Company
Cervical Cancer by FIGO Stage 2018
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate
that adaptive radiotherapy for locally advanced cervical cancer will translate into a
decreased rate of acute gastrointestinal toxicity compared with the historically reported
rate for non-adaptive intensity modulated... expand
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Type: Interventional Start Date: May 2022 |
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants
Brigham and Women's Hospital
Genetic Predisposition to Disease
Hereditary Diseases
This research study is exploring the use of genomic sequencing in the newborn period to
screen healthy babies for current and future health risks. The study will enroll a
diverse cohort of 500 healthy infants and their parents from Boston, MA; New York City,
NY; and Birmingham, AL. A small blood sample... expand
This research study is exploring the use of genomic sequencing in the newborn period to screen healthy babies for current and future health risks. The study will enroll a diverse cohort of 500 healthy infants and their parents from Boston, MA; New York City, NY; and Birmingham, AL. A small blood sample will be collected from each infant, and whole genome sequencing will be performed in 1/2 of the cohort following a randomized controlled trial design. 3 months later, the randomization status and sequencing results will be shared with parents and pediatricians. Investigators will study the medical, behavioral, and economic outcomes of genomic sequencing to better understand how this technology can be implemented in outpatient primary care settings. Type: Interventional Start Date: Dec 2022 |
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
University of Alabama at Birmingham
Hiv
Alcohol Problem
This study is designed to examine the efficacy of a brief intervention plus a
cognitive-behavioral intervention compared to brief intervention alone to address
unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among
people living with HIV in Alabama. expand
This study is designed to examine the efficacy of a brief intervention plus a cognitive-behavioral intervention compared to brief intervention alone to address unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among people living with HIV in Alabama. Type: Interventional Start Date: May 2023 |
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
University of Alabama at Birmingham
Sickle Cell Disease
Renal Disease
Glomerular Disease
The investigators will attempt to develop a more accurate equation to estimate eGFR in
pediatric and adult sickle cell patients expand
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients Type: Observational Start Date: May 2021 |
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care
University of Alabama at Birmingham
HIV
AIDS
Smoking Cessation
To determine the efficacy of an algorithm designed to recommend smoking cessation-related
pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS. expand
To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS. Type: Interventional Start Date: Aug 2020 |
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and...
University of Alabama at Birmingham
PreDiabetes
One in three American adults have prediabetes, and up to 70% of adults with prediabetes
eventually develop type 2 diabetes. With the high cost of treating diabetes,
cost-effective approaches are needed to reduce the incidence of diabetes. One new
strategy may be to change when people eat. Studies... expand
One in three American adults have prediabetes, and up to 70% of adults with prediabetes eventually develop type 2 diabetes. With the high cost of treating diabetes, cost-effective approaches are needed to reduce the incidence of diabetes. One new strategy may be to change when people eat. Studies in rodents suggest that a form of intermittent fasting that limits eating to a short time period each day and involves fasting for the rest of the day (time-restricted eating; TRE) improves blood sugar control and cardiovascular health. Preliminary studies suggest that TRE also improves blood sugar, weight loss, and cardiovascular health in humans. This study will be the first full-scale, controlled feeding trial to determine whether TRE can improve 24-hour blood sugar control, 24-hour blood pressure, and cardiovascular disease risk factors even when food intake is matched to the control group. This clinical trial will also determine whether the benefits of TRE depend on the time of day that people eat. Participants will be assigned to one of three groups: (1) 'Early TRE' (eat between ~8 am-3 pm), (2) 'Mid-day TRE' (eat between ~1 pm - 8 pm), or (3) Control Schedule (~8 am - 8 pm) for 8 weeks. All food will be provided and matched between groups. Type: Interventional Start Date: Aug 2020 |
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
ProDa BioTech, LLC
Pancreatic Ductal Carcinoma
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the
safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and
nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal
adenocarcinoma (PDAC) expand
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC) Type: Interventional Start Date: Sep 2023 |
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
University of Alabama at Birmingham
Parathyroid Dysfunction
Adenoma
The aim of this study is to determine if fluorescence with or without indocyanine green
can facilitate safe and accurate thyroid and parathyroid surgery. expand
The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery. Type: Interventional Start Date: Apr 2024 |
Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)
University of Alabama at Birmingham
Kidney Diseases
Cardiometabolic Risk Factors
We seek to explore the feasibility and acceptability of participation in a
decision-support training program led by lay navigators. ImPart-Multi, an
education-telehealth-based, is designed to empower Black chronic kidney disease patients
(CKD) patients and their care partner to seek the resources... expand
We seek to explore the feasibility and acceptability of participation in a decision-support training program led by lay navigators. ImPart-Multi, an education-telehealth-based, is designed to empower Black chronic kidney disease patients (CKD) patients and their care partner to seek the resources and support needed to be activated allies when making health-related decisions. Participants, based on random assignment, will participate in survey completion at study start and at 12 and 24 weeks of enrollment, and will complete 1, 3, or 4 education sessions via telehealth or audio connection. Participants will also complete an interview to share their thoughts on the program and other factors of interest. Type: Interventional Start Date: Mar 2024 |
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
University of Texas Southwestern Medical Center
Cocaine Use Disorder
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a
combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine
(XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine
use disorder (CUD). expand
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD). Type: Interventional Start Date: Apr 2023 |
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
University of Alabama at Birmingham
HER2-positive Breast Cancer
The purpose of the study is to see if using an investigational drug called [18F]FMISO
with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin)
on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This
study is for imaging purposes only and... expand
The purpose of the study is to see if using an investigational drug called [18F]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future. Type: Interventional Start Date: Apr 2025 |
Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
Eyenovia Inc.
Myopia
This study evaluates the progression of myopia in participants using microdosed atropine
0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer
study medication daily in each eye for 48 months. Efficacy and safety assessments will be
performed at visits scheduled for... expand
This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year. Type: Interventional Start Date: Jun 2019 |
Cognitive Training Intervention and Attitudes Towards Genetics
University of Alabama at Birmingham
Cognitive Impairment
Hematologic Neoplasms
Hematopoietic Cell Transplant
A pilot study to evaluate feasibility of enrollment of patients in an intervention to
improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors
using the cognitive training Lumosity program. In addition, patients' interest in
receiving information regarding genetic risk... expand
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured. Type: Interventional Start Date: Aug 2017 |
Retraining and Control Therapy (ReACT) R33 Phase
University of Alabama at Birmingham
Convulsion, Non-Epileptic
The purpose of this study is to assess sense of control and catastrophic symptom
expectations as targets for Retraining and Control Therapy (ReACT- an intervention
focused on changing behaviors and thoughts) for treatment of pediatric psychogenic
non-epileptic seizures (PNES, episodes resembling epileptic... expand
The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of pediatric psychogenic non-epileptic seizures (PNES, episodes resembling epileptic seizures but with no correlated epileptiform activity). 11-18-year-olds diagnosed with PNES will engage in twelve sessions of either ReACT or supportive therapy. Sense of control over actions will be measured by the magic and turbulence task, a well-validated measure of sense of control. Participants will complete the cold pressor test (CPT) in which participants hold their hand in cool water for as long as possible up to 3 minutes. Catastrophic symptom expectations in response to the CPT will be measured by Pain Catastrophizing Scale for Children (PCS-C), pain tolerance (time with hand in water) and cortisol response. Target assessments occur 7 days before treatment, 7 days after 12th treatment session, and 2 months after the 12th treatment session. Long term follow-up assessments will occur 6 months and 12 months after the 12th treatment session. PNES frequency will be measured from 30 days before to 12 months after treatment. Type: Interventional Start Date: Mar 2024 |
Cold Agglutinin Disease Real World Evidence Registry
Sanofi
Cold Agglutinin Disease (CAD)
Cold Agglutinin Syndrome (CAS)
This is a multinational, multi-center, observational, prospective, longitudinal disease
registry designed to collect data on participants with cold agglutinin disease (CAD) or
cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated
with sutimlimab are expected to take... expand
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry. Type: Observational [Patient Registry] Start Date: Dec 2019 |
Functional Outcomes From Diets in Multiple Sclerosis
University of Alabama at Birmingham
Relapsing Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
The purpose of this study is to test the effects of two dietary interventions, glycemic
load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and
anxiety in adults with multiple sclerosis (MS). The investigators will also explore the
how the diet interventions impact... expand
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact inflammation, immunity, and metabolic biomarkers. Type: Interventional Start Date: Mar 2023 |
- Previous
- Next